Search

Author/Creator Dinavahi, R.

1. EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGN. (17th June 2021)

Authors:
Choquet, S.; Pérez‐Simón, J. A.; Worel, N.; Chaganti, S.; Dinavahi, R.; Guzman‐Becerra, N.; Navarro, W.; Sun, Y.; Gamelin, L.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE). (23rd June 2022)

Authors:
Prockop, S.; Beitinjaneh, A.; Choquet, S.; Dahiya, S.; Dinavahi, R.; Farah, R.; Gamelin, L.; Ghobadi, A.; Mehta, A.; Nayak, P.; Reshef, R.; Satyanarayana, G.; Stiff, P.; Ye, W.; Mahadeo, K. M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
157
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search